AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte.

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.

ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow.

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade

ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.

AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?

AngioDynamics announces the receipt of CPT Category I code for IRE technology.

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife® System in partnership with t.

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liver. The decision by the American Medical Association's (“AMA”) CPT® Editorial Panel will facilitate reimbursement for h.

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.

Here's Why You Should Add AngioDynamics Stock to Your Portfolio

Investors didn't like the medical technology company's fiscal 2025 Q1 update.

Why AngioDynamics Stock Is Crashing Today

AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 First Quarter Earnings Call.

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Levi Strauss

Ingevity

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.

AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights   Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million.

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Atour Lifestyle Holdings Ltd

Marex Group PLC

Opera Ltd - ADR

Pampa Energia

MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.

New Strong Buy Stocks for September 30th

AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.

ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for Treatment of Acut.

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to.

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Arcturus Therapeutics

First Mid-Illinois Bancshares

M/I Homes

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

New Strong Buy Stocks for September 13th

Affirm

Cerence

Diversified Energy Co PLC

G-III Apparel Group

DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.

New Strong Buy Stocks for September 9th

ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.

News for AngioDynamics Stock (ANGO)